ArticleClinical chemistry2004
Antigenicity analysis of different regions of the severe acute respiratory syndrome coronavirus nucleocapsid protein.
Article in Clinical chemistry, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 62 citations in OpenAlex.
- Analysis of 6.4 million SARS-CoV-2 genomes identifies mutations associated with fitness.Science (New York, N.Y.) · 2022Article
- Analysis of 6.4 million SARS-CoV-2 genomes identifies mutations associated with fitness.medRxiv : the preprint server for health sciences · 2022Article
- Article
- Immunogenicity and crossreactivity of antibodies to the nucleocapsid protein of SARS-CoV-2: utility and limitations in seroprevalence and immunity studies.Translational research : the journal of laboratory and clinical medicine · 2021Article
- Immunologic Testing for SARS-CoV-2 Infection from the Antigen Perspective.Journal of clinical microbiology · 2021Review
- Comparative research on nucleocapsid and spike glycoprotein as the rapid immunodetection targets of COVID-19 and establishment of immunoassay strips.Molecular immunology · 2021Article
- Article
- Serological assays for emerging coronaviruses: challenges and pitfalls.Virus research · 2014Review
- Antibody-dependent SARS coronavirus infection is mediated by antibodies against spike proteins.Biochemical and biophysical research communications · 2014Article
- Yeast surface display-based microfluidic immunoassay.Sensors and actuators. B, Chemical · 2012Article
- A double-inactivated severe acute respiratory syndrome coronavirus vaccine provides incomplete protection in mice and induces increased eosinophilic proinflammatory pulmonary response upon challenge.Journal of virology · 2011Article
- Serological characterization of guinea pigs infected with H3N2 human influenza or immunized with hemagglutinin protein.Virology journal · 2010Article
- Interactions of SARS coronavirus nucleocapsid protein with the host cell proteasome subunit p42.Virology journal · 2010Article
- Enhancing immune responses against SARS-CoV nucleocapsid DNA vaccine by co-inoculating interleukin-2 expressing vector in mice.Biotechnology letters · 2009Article
- Protein microarrays: high-throughput tools for proteomics.Expert review of proteomics · 2009Review
- Article
- Applications of microarrays in pathogen detection and biodefence.Trends in biotechnology · 2009Review
- Search for potential target site of nucleocapsid gene for the design of an epitope-based SARS DNA vaccine.Immunology letters · 2008Article
- Vaccination of mice with recombinant baculovirus expressing spike or nucleocapsid protein of SARS-like coronavirus generates humoral and cellular immune responses.Molecular immunology · 2008Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe widespread threat of severe acute respiratory syndrome (SARS) to human health has made urgent the development of fast and accurate analytical methods for its early diagnosis and a safe and efficient antiviral vaccine for preventive use. For this purpose, we investigated the antigenicity of different regions of the SARS coronavirus (SARS-CoV) nucleocapsid (N) protein.
methodsThe cDNA for full-length N protein and its various regions from the SARS-CoV was cloned and expressed in Escherichia coli. After purification, all of the protein fragments were printed on glass slides to fabricate a protein microarray and then probed with the sera from SARS patients to determine the reactivity of these protein fragments.
resultsThe full-length protein and two other fragments reacted with all 52 sera tested. Four important regions with possible epitopes were identified and named as EP1 (amino acids 51-71), EP2 (134-208), EP3 (249-273), and EP4 (349-422), respectively. EP2 and EP4 possessed linear epitopes, whereas EP1 and EP2 were able to form conformational epitopes that could react with most (>80%) of the tested sera. EP3 and EP4 also formed conformational epitopes, and antibodies against these epitopes existed in all 52 of the sera tested.
conclusionThe N protein is a highly immunogenic protein of the SARS-CoV. Conformational epitopes are important for this protein, and antigenicity of the COOH terminus is higher than that of the NH(2) terminus. The N protein is a potential diagnostic antigen and vaccine candidate for SARS-CoV.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.